Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Key Highlights
- ➤Hemostemix receives full LARTA approval for commercial Phase 1 VesCell™ study
- ➤Private placement targets C$1,000,000; initial closing raises C$380,500
- ➤Initial closing issues 7,610,000 units at C$0.05 each
- ➤CytoImmune licence abandoned; 20 million contemplated shares were not issued
- ➤CytoImmune moves ACP-01 test-batch production into cleanroom
Expert Statements
Michael Darville, Minister of Health and Wellness of The Bahamas
“a reputable location for regenerative medicine … asserting that The Bahamas cannot lose an opportunity of proximity to the world's largest market for longevity and regenerative therapies.”
Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical development program within The Bahamas' growing longevity and regenerative-medicine sector.
Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection for a non-brokered private placement to raise up to $1,000,000 on the same terms as its previously announced offering. The Company is completing an initial closing of C$380,500 through the issuance of 7,610,000 units at C$0.05 per Unit.
Get started
Create a free account to read the full story.